Description:GS967 is a chemical compound that functions primarily as a selective inhibitor of the cardiac sodium channel NaV1.5, which plays a crucial role in cardiac action potentials and excitability. This compound is notable for its potential therapeutic applications in treating cardiac arrhythmias, particularly in conditions like long QT syndrome. GS967 exhibits a high degree of specificity for NaV1.5 over other sodium channels, which is essential for minimizing side effects associated with broader sodium channel inhibition. The compound is typically characterized by its molecular structure, which includes specific functional groups that contribute to its binding affinity and selectivity. Additionally, GS967 has been studied for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, which are critical for its efficacy and safety profile in clinical settings. As research continues, GS967 may provide insights into novel treatment strategies for various cardiac disorders, highlighting the importance of targeted pharmacological interventions in cardiology.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)-](https://static.cymitquimica.com/products/IN/thumb/DA000SFD.jpg)
![6-(4-(Trifluoromethoxy)Phenyl)-3-(Trifluoromethyl)-[1,2,4]Triazolo[4,3-A]Pyridine](https://static.cymitquimica.com/products/54/thumb/PC108746.jpg)
